

Andrei V Krivtsov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5034293/publications.pdf>

Version: 2024-02-01

59
papers

8,662
citations

126907

33
h-index

161849

54
g-index

65
all docs

65
docs citations

65
times ranked

12798
citing authors

#	ARTICLE	IF	CITATIONS
1	Macrophage polarization in hypoxia and ischemia/reperfusion: Insights into the role of energetic metabolism. <i>Experimental Biology and Medicine</i> , 2022, 247, 958-971.	2.4	9
2	MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. <i>Cancer Discovery</i> , 2022, 12, 1804-1823.	9.4	10
3	Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. <i>Blood</i> , 2020, 136, 1983-1988.	1.4	25
4	Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. <i>Science</i> , 2020, 367, 586-590.	12.6	145
5	A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. <i>Science</i> , 2019, 365, 599-604.	12.6	265
6	A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. <i>Cancer Cell</i> , 2019, 36, 660-673.e11.	16.8	231
7	IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. <i>Cell Stem Cell</i> , 2019, 24, 153-165.e7.	11.1	66
8	LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBP β -dependent enhancers in AML. <i>Blood</i> , 2018, 131, 1730-1742.	1.4	92
9	MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2018, 8, 478-497.	9.4	59
10	Peptidomimetic blockade of MYB in acute myeloid leukemia. <i>Nature Communications</i> , 2018, 9, 110.	12.8	68
11	TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. <i>Nature Genetics</i> , 2018, 50, 83-95.	21.4	156
12	Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. <i>Blood Advances</i> , 2018, 2, 2478-2490.	5.2	12
13	The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. <i>Blood</i> , 2018, 131, 2661-2669.	1.4	313
14	Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026658.	6.2	46
15	Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. <i>Nature Genetics</i> , 2017, 49, 866-875.	21.4	75
16	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. <i>Nature Communications</i> , 2017, 8, 15429.	12.8	55
17	SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. <i>Blood</i> , 2017, 130, 2631-2641.	1.4	102
18	Murine Retrovirally Transduced Bone Marrow Engraftment Models of MLL Fusion-Driven Acute Myelogenous Leukemias (AML). <i>Current Protocols in Pharmacology</i> , 2017, 78, 14.42.1-14.42.19.	4.0	2

#	ARTICLE	IF	CITATIONS
19	A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. <i>Molecular Cell</i> , 2017, 67, 308-321.e6.	9.7	172
20	Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. <i>Nature Medicine</i> , 2016, 22, 672-678.	30.7	301
21	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , 2016, 22, 1488-1495.	30.7	195
22	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". <i>Nature Medicine</i> , 2016, 22, 578-579.	30.7	7
23	Peptidomimetic Blockade of MYB in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3945-3945.	1.4	0
24	Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 436-436.	1.4	0
25	RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program. <i>Blood</i> , 2016, 128, 739-739.	1.4	0
26	Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. <i>Clinical Cancer Research</i> , 2015, 21, 2348-2358.	7.0	57
27	MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. <i>Haematologica</i> , 2015, 100, e190-e193.	3.5	45
28	Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. <i>Cell Stem Cell</i> , 2015, 17, 611-623.	11.1	97
29	Mediator kinase inhibition further activates super-enhancer-associated genes in AML. <i>Nature</i> , 2015, 526, 273-276.	27.8	307
30	A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence. <i>Genes and Development</i> , 2015, 29, 2231-2243.	5.9	32
31	Loss of BAP1 function leads to EZH2-dependent transformation. <i>Nature Medicine</i> , 2015, 21, 1344-1349.	30.7	297
32	Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 88-88.	1.4	0
33	AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes. <i>Cancer Cell</i> , 2014, 26, 896-908.	16.8	153
34	Regulation of HOX gene expression by AF10-mediated conversion of H3K79me1 to H3K79me2. <i>Experimental Hematology</i> , 2014, 42, S30.	0.4	0
35	Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. <i>Blood</i> , 2014, 124, 13-23.	1.4	139
36	Pathprinting: An integrative approach to understand the functional basis of disease. <i>Genome Medicine</i> , 2013, 5, 68.	8.2	13

#	ARTICLE	IF	CITATIONS
37	Myeloid Leukemia Cells With MLL partial Tandem Duplication Are Sensitive To Pharmacological Inhibition Of The H3K79 Methyltransferase DOT1L. <i>Blood</i> , 2013, 122, 1256-1256.	1.4	35
38	Patient Derived Xenograft (PDX) Models Faithfully Recapitulate The Genetic Composition Of Primary AML. <i>Blood</i> , 2013, 122, 1328-1328.	1.4	2
39	Regulation Of Normal and Malignant Hoxa Gene Expression Through Higher H3K79 Methylated States. <i>Blood</i> , 2013, 122, 2492-2492.	1.4	2
40	The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. <i>Nucleic Acids Research</i> , 2012, 40, D984-D991.	14.5	29
41	Can One Cell Influence Cancer Heterogeneity?. <i>Science</i> , 2012, 338, 1035-1036.	12.6	3
42	EV11 is critical for the pathogenesis of a subset of MLL-AF9 rearranged AMLs. <i>Blood</i> , 2012, 119, 5838-5849.	1.4	76
43	MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L. <i>Cancer Cell</i> , 2011, 20, 66-78.	16.8	791
44	MLL-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1. <i>Clinical Cancer Research</i> , 2010, 16, 2122-2130.	7.0	39
45	The Wnt/ β -Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML. <i>Science</i> , 2010, 327, 1650-1653.	12.6	675
46	Transformation from Committed Progenitor to Leukemia Stem Cells. <i>Annals of the New York Academy of Sciences</i> , 2009, 1176, 144-149.	3.8	17
47	HOXA9 is required for survival in human MLL-rearranged acute leukemias. <i>Blood</i> , 2009, 113, 2375-2385.	1.4	292
48	Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis. <i>Blood</i> , 2009, 113, 3461-3471.	1.4	51
49	Gene Expression Profiling of Leukemia Stem Cells. <i>Methods in Molecular Biology</i> , 2009, 538, 231-246.	0.9	6
50	Cell of Origin Influences Leukemia Stem Cell Phenotype.. <i>Blood</i> , 2009, 114, 3459-3459.	1.4	6
51	H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias. <i>Cancer Cell</i> , 2008, 14, 355-368.	16.8	494
52	Jedi a novel transmembrane protein expressed in early hematopoietic cells. <i>Journal of Cellular Biochemistry</i> , 2007, 101, 767-784.	2.6	21
53	MLL translocations, histone modifications and leukaemia stem-cell development. <i>Nature Reviews Cancer</i> , 2007, 7, 823-833.	28.4	1,039
54	Hoxa9+Meis1a Efficiently Transform Hematopoietic Stem Cells but Not Committed Progenitors.. <i>Blood</i> , 2007, 110, 3375-3375.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature, 2006, 442, 818-822.	27.8	1,317
56	Induction of Bim Facilitates Apoptosis in Leukemia Cells Treated with HDAC Inhibitors.. Blood, 2006, 108, 1994-1994.	1.4	0
57	HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias.. Blood, 2006, 108, 734-734.	1.4	2
58	Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO Journal, 2005, 24, 368-381.	7.8	111
59	Both SH2 Domains Are Involved in Interaction of SHP-1 with the Epidermal Growth Factor Receptor but Cannot Confer Receptor-directed Activity to SHP-1/SHP-2 Chimera. Journal of Biological Chemistry, 1997, 272, 5966-5973.	3.4	95